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Background: Depression is common in Parkinson’s disease (PD), and has a significant impact on the functional
level of those affected. It is well studied in Western populations but data from Asia is limited. This study aims to
estimate the prevalence of depression among PD patients attending a tertiary care outpatient clinic in Sri Lanka
and identify potential risk factors.
Methods: One hundred and four consecutive idiopathic PD patients as defined by the United Kingdom Parkinson’s
Disease Society Brain Bank Diagnostic Criteria were recruited to the study. An interviewer administered
questionnaire, the Hoehn-Yahr staging scale and the Schwab-England Activities of Daily Living Scale (SEADL) were
used for assessment. Depression was diagnosed through a semi-structured clinical interview based on DSM-IV-TR
criteria and all subjects were rated with the Montgomery-Asberg Depression Rating Scale (MADRS).
Results: The prevalence of depression in the study population was 37.5%. Among the depressed 12 (30.8%) had
mild depression, 21 (53.8%) moderate depression and 6 (15.4%) had severe depression. Depression was significantly
associated with the stage of PD, functional impairment, civil status, educational level, caregiver dependence and
concomitant diabetes mellitus.
Conclusion: A significant proportion of PD patients suffers from depression. The prevalence rate of depression in
the sample was similar to that reported in previous studies. Depression in PD is significantly associated with
functional impairment.
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Parkinson’s disease (PD) is the second commonest neu-
rodegenerative disorder, its prevalence only being less
than that of Alzheimer’s disease [1]. It affects approxi-
mately 1% of individuals older than 55 years [2]. Many
patients with PD have clinically significant non-motor
symptoms such as anxiety, depression, fatigue, sleep dis-
turbance and sensory symptoms [3].
Up to 90% of patients with idiopathic PD experience
psychiatric complications, including major depression [4].
Depression is the most common neuropsychiatric disturb-
ance in PD [5] with its prevalence estimated to be around
35% [6]. It is also the most important predictor of poor
quality of life in PD [1] and the most significant factor as-
sociated with experienced quality of life [7]. These findings* Correspondence: varunidesilva2@yahoo.co.uk
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article, unless otherwise stated.emphasize the need to study the factors associated with
depression in this population.
In comparison to the Western world there is a paucity
of research on PD related psychiatric manifestations in
Asia, especially in the South Asian region. Findings from
Western populations cannot be directly extrapolated to
the population of this region due to significant socio-
cultural differences. This may also be supported by the ob-
servation that rates of depression have been shown to vary
widely between different countries [1]. This underscores
the importance of studying depression in PD in different
countries and in a variety of socio-cultural contexts. To
our knowledge, to date, only one study has been con-
ducted in the South Asian region on this subject, which
found a higher prevalence of depression, greater overall
disability and inferior quality of life among PD patients
compared to a control group of patients with other
chronic medical illnesses [8]. The present study, the firstCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lence of major depression in PD and identify potential risk
factors in a local and regional context.
Methods
The study was conducted in the outpatient Movement
Disorder and Neurology clinics of the premier hospital
in Sri Lanka, a tertiary care centre, over a period of
3 months. One hundred and four consecutive patients
with idiopathic PD, satisfying the required number de-
rived from sample size calculation and diagnosed accord-
ing to United Kingdom Parkinson’s Disease Society Brain
Bank Diagnostic Criteria (UK-PDS-BB) [9], were recruited
to the study after excluding patients with severe speech
difficulty. Clinical records of the selected patients were pe-
rused to establish the initial presentation and to under-
stand the initial assessor’s view about the diagnosis.
Informed consent was obtained from the study partici-
pants. Ethical clearance was obtained from the Ethics
Committee of National Hospital of Sri Lanka.
Data related to socio-demographics, PD and other
health associated factors of the study subjects were re-
corded using an interviewer-administered questionnaire.
The severity of PD was graded according to Hoehn-Yahr
Staging system [10]. Functional impairment was esti-
mated using the Schwab and England Activities of Daily
Living scale (SEADL) [11]. The rating was done by the
first author based on the information obtained from the
patient and caregiver. A semi-structured clinical interview
was conducted by the first author and major depression
was diagnosed according to DSM-IV-TR criteria [12]. The
DSM-IV-TR diagnosis of depressive disorder was consid-
ered the gold standard. Irrespective of the presence or ab-
sence of depression all participants were rated using the
Montgomery-Asberg Depression Rating Scale (MADRS)
[13]. The MADRS scores were utilized primarily to rate
the severity of depression in those diagnosed with the dis-
order. The MADRS cut-off scores used to rate severity
were ≤20: mild depression, 21–34: moderate depression
and above 34: severe depression [14]. The MADRS was
not translated into the local languages as it was scored by
the investigators. While the interview was conducted in
local languages, the assessments were made in English by
the investigators. The investigators are bilingual and con-
duct clinical assessment interviews in the local languages
and record data and management plans in English. The
validation of the MADRS score using a structured clinical
interview are reported in the results section.
Statistical analysis of data
Statistical analysis included descriptive statistics, Pearson’s
chi-square test, the Student’s independent t-test and univar-
iate logistic and linear regression analyses. The Chi–squaretest examined the association between categorical variables.
Logistic regression analysis calculated the odds ratio for
each event in order to examine the possible association
of demographic and clinical parameters with depression.
Linear regression models were applied to assess the pre-
dictive power of variables such as age at assessment to-
wards depression. The level of statistical significance
was p < 0.05. All analyses were performed with the Stat-
istical Package for Social Sciences (SPSS) version 16.0
for Windows.
Results
Description of socio-demographic variables
The socio-demographic data of the sample are reported
in Table 1. The total number of study participants was
104. The mean age of the sample was 62.5 years (SD ± 9)
(age range 44 to 83 years). The largest occupational group
in the sample comprised of skilled workers, who num-
bered 35 (33.7% of the total sample). Occupational classes
were assigned as defined by the Registrar-General Social
Classes Classification [15].
Prevalence of major depressive disorder
Thirty-nine subjects were diagnosed with a major depres-
sive episode according to DSM-IV-TR criteria. Thus the
prevalence of depression in this population was 37.5%
(95% CI 28.04-46.96).
The MADRS scores ranged from 0 to 46. The mean
MADRS score of the total sample was 13.14 (SD ± 11.81).
In the depressed and non-depressed groups the mean
MADRS scores were 26.08(SD ± 8.3) and 5.38(SD ± 4.5)
respectively. Among the depressed, 12 (30.8%) had mild
depression, 21 (53.8%) suffered moderate depression and
6 (15.4%) had severe depression, when categorised on the
MADRS score.
Major depressive disorder and socio-demographic
characteristics
Unadjusted odds ratios obtained from logistic regression
analysis are reported in Table 1. The mean age of the de-
pressed, 61.87 years (SD ± 8.46), was not significantly
different from that of the non-depressed individuals
(62.92 years) (SD ± 9.4) (t = .571, p = .569). Age was not a
significant predictor of depression in linear regression
analysis.
Description of clinical variables
The clinical data are shown in Table 2. Only two subjects
reported a family history of mental illness. The majority of
the 17 subjects who reported past psychiatric issues had
substance related problems mainly in the form of depend-
ence but were currently abstinent and 4 (3.8%) had a his-
tory of depressive episodes (data not shown in the table).
Table 1 Association between major depressive disorder and socio-demographic characteristics
Variables Total no (%) Depression OR (95% CI) p value
Yes (n,%) No (n,%)
Age category (years)
≤50 14(13.5%) 4(28.6%) 10(71.4%) 1 0.136
51-60 20(19.2%) 12(60.0%) 8(40.0%) 3.75(0.86-16.22)
61-70 45(43.3%) 13(28.9%) 32(71.1%) 1.02(0.27-3.82)
71-80 24(23.1%) 10(41.7%) 14(58.3%) 1.79(0.43-7.35)
> 80 1(0.96%) 0(0.0%) 1(100.0%) 0
Gender
Male 64(61.5%) 23(35.9%) 41(64.1%) 1 0.677
Female 40(38.5%) 16(40.0%) 24(60.0%) 1.188(0.52-2.67)
Civil status
Single 10(9.6%) 2(20.0%) 8(80.0%) 1 0.039
Married 74(71.2%) 29(39.2%) 45(60.8%) 2.57(0.51-13.00)
Separated/divorced 6(5.7%) 5(83.3%) 1(16.7%) 20.00(1.41-282.4)
Widowed 14(13.5%) 3(21.4%) 11(78.6%) 1.09(0.14-8.12)
Level of education
Up to GCE O/L 81(77.9%) 35(42.7%) 47(57.3%) 3.35(1.04-10.78) 0.035
GCE A/L & higher 22(21.1%) 4(18.2%) 18(81.8%) 1
Currently employed
Yes 20(19.2%) 6(30.0%) 14(70.0%) 1 0.441
No 84(80.8%) 33(39.3%) 51(60.7%) 1.51(0.52-4.32)
Reason for unemployment
Never employed 1(1.2%) 0(0.0%) 1(100.0%) 0.00 0.433
Retired with age 25(29.7%) 7(28.0%) 18(72.0%) 0.45(0.11-1.83)
Quit due to PD 45(53.6%) 20(44.4%) 25(55.6%) 0.93(0.27-3.22)
Other reasons 13(15.5%) 6(46.2%) 7(53.8%) 1
Monthly income in LKR
≤10,000 33(31.7%) 16(48.5%) 17(51.5%) 2.04(0.78-5.36) 0.285
10,001-20,000 33(31.7%) 11(33.3%) 22(66.7%) 1.08(0.4-2.93)
>20,000 38(36.5%) 12(31.6%) 26(68.4%) 1
OR – Odds ratio; GCE O/L- General Certificate in Education Ordinary Level,
GCE A/L - General Certificate in Education Advanced Level; LKR -Sri Lankan Rupee,
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In addition to the commonly used anti-Parkinsonian
medications such as levodopa (n = 102, 98.1%), benzhexol
(n = 96, 92.3%), amantadine (n = 3, 2.9%) and ropinirole
(n = 21, 20.2%), patients were also receiving medications
such as bromocriptine, madopar, clonazepam and propro-
nolol. Two subjects (1.9%) were treated only with benz-
hexol. Sixty-seven (64.4%) were on 2 anti-Parkinsonian
medications, with over 90% of this group receiving the
benzhexol and levodopa combination, while 23.1% were
on a combination of 3 medications. Thirty-nine patients
(37.5%) were on cardiotropics, antihypertensives or oral
hypoglycaemics.Diabetes mellitus (n = 12, 11.5%), hypertension (n = 29,
27.9%), heart disease (n = 8, 7.7%), epilepsy (n = 2, 1.9%)
and stroke (n = 1, 0.96%) were significant chronic medical
illnesses concomitant with PD in the sample.
Major depressive disorder and Parkinson’s disease
correlates
Table 2 shows the association between major depressive
disorder and PD and other clinical correlates. Dependence
on a caregiver was determined by accounts from patients
and accompanying relatives or friends with specific ques-
tions focusing on activities of daily living. Among the 79
caregiver dependent patients, 69 (87.3%) were cared by
Table 2 Association between major depressive disorder and Parkinson's disease and other clinical correlates
Variables Total no (%) Depression OR (95% CI) p value
Yes No
Age of PD onset (years)
<40 10(9.6%) 4(40.0%) 6(60.0%) 1 0.813
41-50 20(19.2%) 9(45.0%) 11(55.0%) 1.22(0.26-5.73)
51-60 42(40.4%) 13(31.0%) 29(69.0%) 0.67(0.16-2.79)
61-70 26(25.0%) 11(42.3%) 15(57.7%) 1.10(0.24-4.85)
>70 6(5.8%) 2(33.3%) 4(66.7%) 0.75(0.09-6.23)
Duration of PD (years)
< 5 42(40.4%) 28(66.7%) 14(33.3%) 1 0.114
5 to 10 28(26.9%) 13(46.4%) 15(53.6%) 2.30(0.86-6.15)
> 10 34(32.7%) 24(70.6%) 10(29.4%) 0.83(0.31-2.21)
Levodopa dose (mg/day)
< 250 15(14.4%) 4(26.7%) 11(73.3%) 1 0.8
250 - 500 41(39.4%) 16(39.0%) 25(61.0%) 1.76(0.47-6.49)
500 - 750 22(21.2%) 10(45.5%) 12(54.5%) 2.29(0.55-9.47)
750 - 1000 15(14.4%) 5(33.3%) 10(66.7%) 1.37(0.28-6.60)
1000 - 1250 9(8.7%) 4(44.4%) 5(55.6%) 2.20(0.38-12.57)
Ropinirole treatment
Yes 21(20.2%) 11(52.4%) 10(47.6%) 10(47.6%) 0.115
No 83(79.8%) 28(33.7%) 55(66.3%) 55(66.3%)
Diabetes
Yes 12(11.5%) 9(75.0%) 3(25.0%) 6.2(1.56-24.5) 0.004
No 92(88.5%) 30(32.6%) 62(67.4%) 1
Significant chronic medical illness comorbid with PD
Yes 48(46.2%) 22(45.8%) 26(54.2%) 1.96 0.086
No 56(53.8%) 17(30.4%) 39(69.6%) 1
Hoehn-Yahr stage
I and II 24(23.1%) 2(8.3%) 22(91.7%) 1 0.003
III 55(52.9%) 27(49.1%) 28(50.9%) 10.61(2.27-49.53)
IV and V 25(24.0%) 10(40.0%) 15(60.0%) 7.33(1.40-38.33)
Schwab-England score (%)
≥80 43(41.4%) 8(18.6%) 35(81.4%) 1 0.008
50-70 45(43.3%) 24(53.3%) 21(46.7%) 5.00(1.90-13.13)
30-40 12(11.5%) 5(41.7%) 7(58.3%) 3.12(0.78-12.43)
≤20 4(3.8%) 2(50.0%) 2(50.0%) 4.37(0.53-35.90)
Caregiver
Independent 25(24.0%) 5(20.0%) 20(80.0%) 1 0.038
Dependent 79(76.0%) 34(43.0%) 45(57.0%) 3.02(1.03-8.86)
OR – Odds ratio.
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3 (3.8%) by non-relatives.
Only eight of the 39 depressed subjects were receiving
anti-depressants at the time of assessment. The most
frequently prescribed anti-depressant was amitriptyline
(average dose ≤25 mg/day).Major depressive disorder and level of functioning
Using the SEADL scale, the patients’ level of functioning
was rated by the investigator. About 41% of patients had
retained 80% function, which corresponds to almost
independent functioning despite slowness resulting in
doubling of time for completing activities. The mean
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nificantly lower than that of the non-depressed
(69.69%) (t = 2.289, p = 0.024).
Sensitivity and specificity of MADRS
As the MADRS scores were available for all patients,
post hoc we decided to determine the sensitivity and spe-
cificity of the MADRS as a diagnostic tool for DSM-IV-
TR diagnosis of major depressive disorder in PD. In a
previous study, a MADRS score ≥18 had been identified
as a good diagnostic cut-off in PD populations [16]. At
this cut-off MADRS showed a sensitivity of 89.7% and a
specificity of 100% when applied to our data (Table 3).
Discussion
This study attempted to determine the prevalence of de-
pression and identify potential risk factors in the PD
population in Sri Lanka. The prevalence of major depres-
sive disorder in the study population was 37.5%, similar to
the rates reported in most Western populations [3,5,6].
The following factors had significantly increased the odds
of developing depression: Hoehn-Yahr stage, functional
impairment, civil status, level of education, caregiver de-
pendence and concomitant diabetes mellitus. More than
half of the depressed subjects were moderately depressed.
Evidence suggests depression is usually milder in this
population [17,18].
In comparison to the majority of studies done in Asia
which utilized assessment scales for the diagnosis of de-
pression, the present study used a semi-structured DSM-
IV-TR based clinical interview for this purpose. A study
from Taiwan [19], which also used an interview based as-
sessment, reported a frequency of major depressive dis-
order of 16.5%, and major and other depressive disorders,
taken together, of 42.2%.
Studies using rating scales to diagnose depression re-
port a higher prevalence than those which use a struc-
tured clinical interview and diagnostic criteria [1,20]. A
study from India using MADRS and the Beck Depression
Inventory (BDI) found the rates as 54% and 49% respect-
ively [8]. Other studies have reported rates of depression
of 46% from the Philippines using the MADRS [21],
56% from Japan using the BDI-II [22] and BDI [23] and
65% using the Zung Self-Rating Depression Scale [24]Table 3 Sensitivity and specificity of MADRSi
DSM-IV-TR
Depressed Not depressed Total
MADRS (≥18) Depressed 35 0 35
Not depressed 4 65 69
Total 39 65 104
MADRS - Montgomery-Asberg Depression Rating Scale.
DSM-IV-TR - Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,
Text Revision.and 21% in China using the Hamilton Rating Scale for
Depression [25]. Interestingly in another study from
Japan among the 38% identified as depressed by BDI-II,
nearly 75% did not show depressed mood [26].
We could not find an association between major depres-
sion in PD and age, gender, employment status, occupa-
tional class, reasons for unemployment, income, past
psychiatric history, age of PD onset, duration of PD,
levodopa dose, ropinirole treatment or the presence of
concomitant other major medical illnesses. Among the
anti-Parkinsonian agents ropinirole was given special
consideration as it is commonly used to treat disabling
dopa induced dyskinesia [27,28], but also appears to ameli-
orate depressive symptoms in PD [27].
The prevalence of depression was higher in Hoehn-Yahr
stages III, IV and above. Similar findings have been re-
ported previously [2,17]. It was highest in stage III possibly
because this is the stage where the debility becomes
marked. Though the rise in the rate of depression would
be expected to be linear as the disability increases this was
not observed. This is possibly due to the inability of the
severely disabled to physically attend the clinic resulting
in a lesser number of patients in severe stages participat-
ing in the study which may have influenced the results.
Existing views about the association between the severity
of PD and depression are contradictory: some studies re-
ported it as positive [2,17,19], while others showed no as-
sociation [29].
The putative association between functional impairment
and depression has been a source of debate for long. De-
pression has been commonly found to be correlated
with increased impairment in activities of daily living
[2,17,19,20] and self-rated disability has been identified
as the greatest predictor of depressive symptoms [29].
The relationship between depression and functional im-
pairment in PD may be reciprocal.
Our results indicate that depression in PD is signifi-
cantly associated with a state of dependence in the af-
fected population. There could be two explanations for
this: while dependence due to physical debility can give
rise to depression, depression with low motivation and
reduced activity could also make people dependent on
others. Among the large number of patients who were
caregiver dependent all but one had informal caregivers,
which highlights the customs of Sri Lankan society where
most of its elderly and feeble members are cared for within
a close family network, without being institutionalized.
The association between diabetes mellitus and depres-
sion in PD is an important finding from this study,
which has not been widely reported. Depression and dia-
betes commonly co-occur in the general population with
rates of depression twice as high in people with diabetes
compared to those without [30]. The rate of depression
among PD patients with diabetes in our study is 75%.
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very high rate merits further exploration regarding the
possible mechanisms underlying this comorbidity.
About 30% of our study population were categorised
under early-onset PD (onset ≤ age 50) and about 10% de-
veloped the illness before 40 years. Most studies reported
rates between 3%-5% for an onset ≤ 40 years, while in
Japan higher rates, up to 10%, were reported [31]. It would
appear that the rates observed in our study are elevated in
comparison to Western studies. We speculate that the
complexity of early onset PD leads to increased referrals
to tertiary care centres, like our study centre; hence the
over representation. However, a distinct type of PD preva-
lent among Asian populations is also a possibility, given
the high rates noted in the Japanese study.
Only 20% of depressed subjects were on antidepres-
sants at the time of assessment which draws attention to
how depression is poorly identified and treated in neur-
ology settings. The actual number treated might have
been lower as it is possible that low dose antidepressants
were prescribed for chronic pain instead of depression
in some patients. Depression in PD is commonly found
to be under-recognized and under-treated [3,5].
Overall our findings are in keeping with what is re-
ported in Western populations, in relation to prevalence
and associated factors of depression in PD. Our study
population showed some unique or less commonly re-
ported characteristics such as a higher proportion of
early onset PD and association of depression with dia-
betes. These characteristics merit further inquiry to as-
certain whether they are replicated regionally and
globally. Further, the differences in depression between
cultures may be in the expression, and studying the
phenomenology of depression in PD across cultures
maybe useful.
Strengths and limitations
A major strength of this study is using a diagnostic cri-
teria based clinical interview as the gold standard for
diagnosing depression which was not commonly employed
in previous studies. The limitations were the sample being
out-patient and largely urban and therefore possibly not
being representative of the general population, the modest
sample size which could have led to the wide confidence
intervals in some results, the potential confounding effect
of subtle cognitive impairment on the presentation and
assessment of depression and hospital based sampling
likely to be yielding a higher prevalence of depression,
as community based studies tend to find lower rates
[1,20,32].
The implications for practice from the study are the
need for greater awareness among clinicians regarding de-
pression in PD, its early detection and the need for inter-
vention. Larger, better designed studies are warranted toconclusively study and identify varying psychiatric mani-
festations associated with PD.
Conclusion
In conclusion this first study in Sri Lanka on PD popula-
tion found that a significant proportion of these patients
suffer from major depression. Depression was significantly
associated with a number of socio-demographic and clin-
ical factors including PD stage and functional impairment;
and was predominantly found in mild to moderate severity.
In addition, the study population displayed some unique
features such as depressive vulnerability in the presence
of diabetes and a higher proportion of early onset PD.
Whether there is a regional effect in these findings and
possible underlying mechanisms for them need further
exploration.
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